<?xml version="1.0" encoding="UTF-8"?>
<p>While the incidence of human African trypanosomiasis is at a historic low and a new drug, fexinidazole (
 <xref rid="B51" ref-type="bibr">Mesu et al., 2018</xref>), has recently received positive opinion by the European Medicines Agency, the prospects are slightly gloomy for other protozoal diseases. Chagas’ disease has reached global dimensions (“WHO | Epidemiology” n.d.), and leishmaniasis as well (“Leishmaniasis” n.d.). Sudan has the highest incidence of leishmaniasis in sub-Saharan countries, with 15,000–20,000 new cases per annum (
 <xref rid="B34" ref-type="bibr">Hotez and Kamath, 2009</xref>). The successful treatment of malaria is threatened by artemisinin-resistant mutants of 
 <italic>P. falciparum</italic>, first reported from Southeast Asia (
 <xref rid="B9" ref-type="bibr">Ariey et al., 2014</xref>; 
 <xref rid="B80" ref-type="bibr">Straimer et al., 2015</xref>; 
 <xref rid="B48" ref-type="bibr">Ménard et al., 2016</xref>) and, more recently, also from Africa (
 <xref rid="B47" ref-type="bibr">Lu et al., 2017</xref>).
</p>
